nach oben

Erschienen in:

01.02.2011

RANTES Deficiency Attenuates Autoantibody-Induced Glomerulonephritis

verfasst von: Chun Xie, Kui Liu, Yuyang Fu, Xiangmei Qin, Geetha Jonnala, Tao Wang, Hong W. Wang, Michael Maldonado, Xin J. Zhou, Chandra Mohan

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Experimental autoimmune nephritis in mice and spontaneous lupus nephritis are both associated with elevated expression of several chemokines in the kidneys. Nevertheless, the role that different chemokines play in mediating renal inflammation is far from complete. This study focuses on elucidating the functional role of RANTES, a chemokine that has been noted to be hyper-expressed within the kidneys, both in experimental renal disease as well as in spontaneous lupus nephritis. To elucidate if RANTES was essential for immune-mediated glomerulonephritis, DBA/1 mice that are highly sensitive to nephrotoxic serum nephritis were rendered RANTES-deficient and then tested for disease susceptibility. Nephritis-sensitive DBA/1 mice expressed more RANTES within the diseased kidneys. Compared to wild-type DBA/1 mice, RANTES-deficient DBA/1 mice developed significantly less proteinuria, azotemia, and renal inflammation, with reduced crescent formation and tubulo-interstitial nephritis. These findings indicate that RANTES ablation attenuates immune-mediated nephritis and suggest that this chemokine could be a potential therapeutic target in these diseases.

Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988;141:1018–25.PubMed

Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine. 1991;3:165–83.CrossRefPubMed

Brown KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol. 1989;142:679–87.PubMed

Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T-lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669–71.CrossRefPubMed

Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol. 1995;101:398–407.CrossRefPubMed

Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem. 1993;268(8):5834–9.PubMed

Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol. 1998;89:44–53.CrossRefPubMed

Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005;52:1907–19.CrossRefPubMed

Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett. 1997;57:117–20.CrossRefPubMed

10.

Barnes DA, Tse J, Kaufhold M, Owen M, Hesselgesser J, Strieter R, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Investig. 1998;101:2910–9.CrossRefPubMed

11.

Okamoto H, Kamatani N. A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats. Rheumatology. 2006;45:230–2.CrossRefPubMed

12.

Snowden N, Hajeer A, Thomson W, Ollier B. RANTES role in rheumatoid arthritis. Lancet. 1994;343:547–8.CrossRefPubMed

13.

Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol. 1999;17:419–25.PubMed

14.

Ellingsen T, Buus A, Kuno Mller B, Stengaard-Pedersen K. In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters. Scand J Rheumatol. 2000;29:216–21.CrossRefPubMed

15.

Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol. 1999;11:553–9.CrossRefPubMed

16.

Proudfoot AEI, Buser R, Borlat F, Alouani S, Soler D, Offord RE, et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem. 1999;274:32478–85.CrossRefPubMed

17.

Anders H-J, Vielhauer V, Kretzler M, Cohen CD, Segerer S, Luckow B, et al. Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol. 2001;12:919–31.PubMed

18.

Schadde E, Kretzler M, Banas B, Luckow B, Assmann K, Schlondorff D. Expression of chemokines and their receptors in nephrotoxic serum nephritis. Nephrol Dial Transplant. 2000;15:1046–53.CrossRefPubMed

19.

Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TNC, Salant DJ, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 Is involved in crescent formation and interstitial fibrosis. J Exp Med. 1997;185:1371–80.CrossRefPubMed

20.

Krensky AM, Ahn Y-T. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol. 2007;3:164–70.CrossRefPubMed

21.

Cockwell P, et al. In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int. 1998;54:827–36.CrossRefPubMed

22.

Furuichi K, et al. Distinct expression of CCR1 and CCR5 in glomerular interstitial lesions of human glomerular disease. Am J Nephrol. 2000;20:291–9.CrossRefPubMed

23.

Xie C, Zhou XJ, Liu X, Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum. 2003;48:1080–92.CrossRefPubMed

24.

Xie C, Sharma R, Wang H, Zhou XJ, Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol. 2004;172:5047–55.PubMed

25.

Fu Y, Du Y, Mohan C. The experimental anti-GBM model as a tool for studying spontaneous lupus nephritis. Clin Immunol. 2007;124:109–18.CrossRefPubMed

26.

Tipping PG, Kitching AR. Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol. 2005;142(2):207–15.CrossRefPubMed

27.

Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, et al. Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. Nephrology (Carlton). 2006;11(3):219–25.CrossRef

28.

Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus. 2003;12(10):766–74.CrossRefPubMed

29.

Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol. 1999;26(3):568–73.PubMed

30.

Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int. 1998;53(6):1631–41.CrossRefPubMed

31.

Gao P, Zhou X-Y, Yashiro-Ohtani Y, Yang Y-F, Sugimoto N, Ono S, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73:273–80.CrossRefPubMed

32.

Panzer U, Schneider A, Wilken J, Thompson DA, Kent SB, Stahl RA. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int. 1999;56:2107–15.CrossRefPubMed

33.

Anders HJ, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol. 2003;170:5658–66.PubMed

34.

Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Investig. 2002;109:251–9.PubMed

35.

Anders HJ, Belemezova E, Elis V, Segerer S, Vielhauer V, Frink M, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-FASlpr mice. J Am Soc Nephrol. 2004;15:1504–13.CrossRefPubMed

36.

Eia V, Luckow B, Vielhauer V, Siveke JT, Linde Y, Sergere S, et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15:337–47.CrossRef

37.

Turner J-E, Paust H-J, Steinmetz OM, Peters A, Meyer-Schwesinger C, Heymann F, et al. CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol. 2008;181:6546–56.PubMed

38.

Ye DQ, et al. Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res. 2005;297:108–13.CrossRefPubMed

39.

Mlynarski WM, et al. Risk of diabetic nephropathy in type I diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes. 2005;54:3331–5.CrossRefPubMed

Titel: RANTES Deficiency Attenuates Autoantibody-Induced Glomerulonephritis
verfasst von: Chun Xie
Kui Liu
Yuyang Fu
Xiangmei Qin
Geetha Jonnala
Tao Wang
Hong W. Wang
Michael Maldonado
Xin J. Zhou
Chandra Mohan
Publikationsdatum: 01.02.2011
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 1/2011
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-010-9470-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Expanding the Universe of Cytokines and Pattern Recognition Receptors: Galectins and Glycans in Innate Immunity

Nicotine Stimulated Dendritic Cells Could Achieve Anti-Tumor Effects in Mouse Lung and Liver Cancer

TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors

Consanguinity Rate and Delay in Diagnosis in Turkish Patients with Combined Immunodeficiencies: a Single-Center Study

IVIg Attenuates TLR-9 Activation in B Cells from SLE Patients